Anzeige
Mehr »
Login
Montag, 20.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
GOLD-MINEN vor Jahrhundert-Hausse?! Diese Aktie sofort kaufen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1W1LG | ISIN: IL0011224156 | Ticker-Symbol:
NASDAQ
17.05.24
21:48 Uhr
1,045 US-Dollar
+0,025
+2,45 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
ICECURE MEDICAL LTD Chart 1 Jahr
5-Tage-Chart
ICECURE MEDICAL LTD 5-Tage-Chart

Aktuelle News zur ICECURE MEDICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
07.05.IceCure Medical Ltd. - 6-K, Report of foreign issuer1
18.04.IceCure Medical (ICCM) Submits Final Cryoablation Data to FDA1
17.04.BTTR, ICCM and SXTC among pre-market losers3
15.04.IceCure submits final breast cancer cryoablation data to FDA1
15.04.IceCure Medical Ltd. - 6-K, Report of foreign issuer1
15.04.IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer77Data presentation at highly influential American Society of Breast Surgeons ("ASBrS") Annual Meeting by Dr. Richard Fine wins Scientific Impact Award as voted by breast surgeons President-Elect of...
► Artikel lesen
04.04.IceCure Medical Ltd (ICCM) Q4 2023 Earnings Call Transcript1
04.04.Earnings call: IceCure reports growth and FDA filings amid challenges1
03.04.IceCure Medical reports FY results1
03.04.IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance68Conference call to be held today at 10:00 am Eastern Time; Focus on U.S. market for ProSense® in breast cancer indication CAESAREA, Israel, April 3, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq:...
► Artikel lesen
03.04.IceCure Medical Ltd. - 20-F, Annual and transition report of foreign private issuers1
02.04.IceCure Medical Ltd. - 6-K, Report of foreign issuer1
19.03.IceCure reports high success in breast cancer cryoablation study1
19.03.IceCure Medical: ICE3 Cryoablation Breast Cancer Study Shows Positive Results-
19.03.IceCure Medical Ltd. - 6-K, Report of foreign issuer-
19.03.IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy69Expects to submit full dataset to the FDA in April for marketing authorization of ProSense® for minimally invasive treatment of early-stage breast cancer Study represents largest cryoablation study...
► Artikel lesen
12.03.IceCure Medical Ltd. - 6-K, Report of foreign issuer1
12.03.IceCure Medical: IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes96Innovating as a global leader in cryoablation technologies, with 42 patents issued and allowed Cryogenic flow control enhances the efficacy and precision of cryoablation procedures CAESAREA, Israel...
► Artikel lesen
04.03.IceCure Medical Ltd. - 6-K, Report of foreign issuer1
26.02.IceCure gains on positive results from study in cancer patients2
Seite:  Weiter >>
44 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1